Lotus Pharmaceutical Co., Ltd. (TPE:1795)

Market Cap	54.80B -24.8%
Revenue (ttm)	20.51B +10.4%
Net Income	4.72B -6.8%
EPS	18.04 -6.2%
Shares Out	262.81M
PE Ratio	11.56
Forward PE	12.39
Dividend	2.56 (1.21%)
Ex-Dividend Date	Aug 11, 2025

Volume	2,332,215
Average Volume	4,663,872
Open	211.00
Previous Close	212.00
Day's Range	208.50 - 216.50
52-Week Range	172.50 - 369.50
Beta	0.28
RSI	31.27
Earnings Date	May 14, 2026

About Lotus Pharmaceutical

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1966
• Employees: 1,099
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1795

Financial Performance

In 2025, Lotus Pharmaceutical's revenue was 20.51 billion, an increase of 10.36% compared to the previous year's 18.58 billion. Earnings were 4.72 billion, a decrease of -6.82%.